Approval · Notice of Compliance 37392 · 2026
JAMP INDAPAMIDE: Notice of Compliance 37392
Issued April 23, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37392
- Date
- April 23, 2026
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- MYLAN INDAPAMIDE (Mylan Pharmaceuticals Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JAMP INDAPAMIDE | 02567849 | Approved |
| JAMP INDAPAMIDE | 02567857 | Approved |
Medicinal ingredients
- INDAPAMIDE 1.25 MG per TAB
- INDAPAMIDE 2.5 MG per TAB